Infacid CREAM

(Fusidic acid)

انفاسیڈ کریم

(فیوسیڈک ایسڈ)

ANTIBIOTIC CREAM 2%

EXTERNAL USE ONLY

صرف بیرونی استعمال کے لئے

Each Gram Contains:
Fusidic acid ... 2% w/w
Product Complies B.P. Specs.

ACTION AND CLINICAL PHARMACOLOGY
Fusidic acid inhibits bacterial protein synthesis by interfering with amino acid transfer from aminoacyl-sRNA to protein on the ribosomes. Fusidic acid may be bacteriostatic or bactericidal depending on inoculum size. Although bacterial cells stop dividing almost within 2 minutes after contact with the antibiotic in vitro, DNA and RNA synthesis continue for 45 minutes and 1 to 2 hours, respectively.

Fusidic acid is virtually inactive against gram-negative bacteria. The differences in activity against gram-negative and gram-positive organisms are believed to be due to a difference in cell wall permeability.

Mammalian cells are much less susceptible to inhibition of protein synthesis by fusidic acid than sensitive bacterial cells. These differences are believed to be due primarily to a difference in cell wall permeability.

INDICATIONS AND CLINICAL USES
The treatment of primary and secondary skin infections caused by sensitive strains of S. aureus, Streptococcus species and C. minutissimum. Primary skin infections that may be expected to respond to treatment with fusidic acid topical include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns.

Appropriate culture and susceptibility studies should be performed. However, while waiting results of these studies and, if antibiotic therapy is considered to be necessary, fusidic acid topical may be administered to those patients in whom an infection caused by susceptible bacteria is suspected. This antibiotic treatment may subsequently require modification once these results become available.

In addition, local concentrations of fusidic acid topical are active against other Corynebacteria, Neisseria, Clostridia and Bacteroides species. No cross-resistance has been observed to date between Infacid and other antibiotics presently in clinical use.

Resistance to fusidic acid has readily been induced in vitro. The development of resistance has also been shown to occur in the clinical setting.

CONTRAINDICATIONS
Sensitivity to fusidic acid and its salts, or lanolin in respect of Infacid cream.

PRECAUTIONS
Treatment of severe or refractory skin lesions should be supplemented with the administration of a systemic antibacterial agent. Use of topical antibiotics occasionally allows overgrowth of non-susceptible organisms. If this occurs, or irritation or sensitization develop, treatment should be discontinued and appropriate therapy instituted. Fusidic acid topical preparations should not be used in or near the eye because of the possibility of conjunctival irritation.

PREGNANCY AND LACTATION
Safety in the treatment of infections during pregnancy has not been established. If administration to pregnant patients is considered necessary, its potential benefits should be weighed against the possible hazards to the fetus. There is evidence to suggest that the drug can penetrate the placental barrier and is detectable in the milk of nursing mothers. Safety of fusidic acid for the treatment of infections in women who are breast-feeding has not been established.

ADVERSE REACTIONS
Mild irritation has occasionally been reported in patients with dermatoses treated with fusidic acid. It was not usually necessary to discontinue therapy. The application of fusidic acid to deep leg ulcers has been associated with pain. Reports of hypersensitivity reactions have been rare.

SYMPTOMS AND TREATMENT OF OVERDOSE
Symptoms and Treatment: Overdosage has not been known to occur during topical therapy with fusidic acid ointment or cream.

DOSAGE AND ADMINISTRATION
Cream: Apply a small amount to the lesion 3 or 4 times daily until favorable results are achieved. Whenever the lesion is to be covered with a gauze dressing, less frequent applications (1 or 2 daily) may be used. In impetigo contagiosa, it has not been shown necessary to remove the crusts before application.

AVAILABILITY
Infacid Cream: Available in 15 g tube.

STORAGE
Store between 15 to 30°C in a dry place, protect from light.
To be dispensed on the prescription of a registered medical practitioner only.
Keep out of the reach of children.

خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔
دوا کو ۱۵ سے ۳۰ ڈگری سینٹی گریڈ کے درمیان خشک جگہ پر رکھیں،
روشنی سے بچائیں۔ صرف رجسٹرڈ ڈاکٹر کے نسخے پر فروخت کریں۔
بچوں کی پہنچ سے دور رکھیں۔

Manufactured by:
Platinum Pharmaceuticals (Pvt) Ltd.
A-20, North Western Industrial Zone,
Bin Qasim, Karachi-75020, Pakistan.

Mfg. Lic No. 000415

QAR No. AW22-0958